The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...

For decades, Americans struggling with pain had two options to find relief: over-the-counter medication such as ibuprofen, which often provided limited reprieve, or prescription opioids, and the ...

Kewalramani cast the moment as an “opportunity to change the paradigm of acute pain management and establish a new standard of care.” Still, Journavx faces some hurdles in winning over ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...